35
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study

      research-article
      , PhD a , b , * , , PhD a , * , , MD a , , MSc c , , PhD d , , BSc e , , MSc f , , MD g , , BSc h , , BSc i , , BSc j , , PhD k , , PhD l , , PhD a , , PhD a , , MS a , , MS a , b , , MSc c , , MSc c , , MSc c , , MSc f , , MSc d , , MSc d , , MPH e , m , , MSc g , , MSc g , , ScD m , n , , PhD n , , PhD o , , PhD o , , MD a , , Prof, PhD k , , PhD l , , PhD h , , Prof, PhD h , , PhD p , , MD n , , MD d , , MD q , r , , PhD j , , MPH i , , PhD c , , Prof, PhD c , , Prof, MBBS f , , PhD f , , Prof, MD g , , MD e , m , , Prof, MD a , * , The MAL-ED Network Investigators
      The Lancet. Global Health
      Elsevier Ltd

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          Enteropathogen infections in early childhood not only cause diarrhoea but contribute to poor growth. We used molecular diagnostics to assess whether particular enteropathogens were associated with linear growth across seven low-resource settings.

          Methods

          We used quantitative PCR to detect 29 enteropathogens in diarrhoeal and non-diarrhoeal stools collected from children in the first 2 years of life obtained during the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) multisite cohort study. Length was measured monthly. We estimated associations between aetiology-specific diarrhoea and subclinical enteropathogen infection and quantity and attained length in 3 month intervals, at age 2 and 5 years, and used a longitudinal model to account for temporality and time-dependent confounding.

          Findings

          Among 1469 children who completed 2 year follow-up, 35 622 stool samples were tested and yielded valid results. Diarrhoeal episodes attributed to bacteria and parasites, but not viruses, were associated with small decreases in length after 3 months and at age 2 years. Substantial decrements in length at 2 years were associated with subclinical, non-diarrhoeal, infection with Shigella (length-for-age Z score [LAZ] reduction −0·14, 95% CI −0·27 to −0·01), enteroaggregative Escherichia coli (−0·21, −0·37 to −0·05), Campylobacter (−0·17, −0·32 to −0·01), and Giardia (−0·17, −0·30 to −0·05). Norovirus, Cryptosporidium, typical enteropathogenic E coli, and Enterocytozoon bieneusi were also associated with small decrements in LAZ. Shigella and E bieneusi were associated with the largest decreases in LAZ per log increase in quantity per g of stool (−0·13 LAZ, 95% CI −0·22 to −0·03 for Shigella; −0·14, −0·26 to −0·02 for E bieneusi). Based on these models, interventions that successfully decrease exposure to Shigella, enteroaggregative E coli, Campylobacter, and Giardia could increase mean length of children by 0·12–0·37 LAZ (0·4–1·2 cm) at the MAL-ED sites.

          Interpretation

          Subclinical infection and quantity of pathogens, particularly Shigella, enteroaggregative E coli, Campylobacter, and Giardia, had a substantial negative association with linear growth, which was sustained during the first 2 years of life, and in some cases, to 5 years. Successfully reducing exposure to certain pathogens might reduce global stunting.

          Funding

          Bill & Melinda Gates Foundation.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          The impoverished gut--a triple burden of diarrhoea, stunting and chronic disease.

          More than one-fifth of the world's population live in extreme poverty, where a lack of safe water and adequate sanitation enables high rates of enteric infections and diarrhoea to continue unabated. Although oral rehydration therapy has greatly reduced diarrhoea-associated mortality, enteric infections still persist, disrupting intestinal absorptive and barrier functions and resulting in up to 43% of stunted growth, affecting one-fifth of children worldwide and one-third of children in developing countries. Diarrhoea in children from impoverished areas during their first 2 years might cause, on average, an 8 cm growth shortfall and 10 IQ point decrement by the time they are 7-9 years old. A child's height at their second birthday is therefore the best predictor of cognitive development or 'human capital'. To this 'double burden' of diarrhoea and malnutrition, data now suggest that children with stunted growth and repeated gut infections are also at increased risk of developing obesity and its associated comorbidities, resulting in a 'triple burden' of the impoverished gut. Here, we Review the growing evidence for this triple burden and potential mechanisms and interventions that must be understood and applied to prevent the loss of human potential and unaffordable societal costs caused by these vicious cycles of poverty.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The MAL-ED study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments.

            (2014)
            Highly prevalent conditions with multiple and complex underlying etiologies are a challenge to public health. Undernutrition, for example, affects 20% of children in the developing world. The cause and consequence of poor nutrition are multifaceted. Undernutrition has been associated with half of all deaths worldwide in children aged <5 years; in addition, its pernicious long-term effects in early childhood have been associated with cognitive and physical growth deficits across multiple generations and have been thought to suppress immunity to further infections and to reduce the efficacy of childhood vaccines. The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) Study, led by the Fogarty International Center of the National Institutes of Health and the Foundation for the National Institutes of Health, has been established at sites in 8 countries with historically high incidence of diarrheal disease and undernutrition. Central to the study is the hypothesis that enteropathogen infection contributes to undernutrition by causing intestinal inflammation and/or by altering intestinal barrier and absorptive function. It is further postulated that this leads to growth faltering and deficits in cognitive development. The effects of repeated enteric infection and undernutrition on the immune response to childhood vaccines is also being examined in the study. MAL-ED uses a prospective longitudinal design that offers a unique opportunity to directly address a complex system of exposures and health outcomes in the community-rather than the relatively rarer circumstances that lead to hospitalization-during the critical period of development of the first 2 years of life. Among the factors being evaluated are enteric infections (with or without diarrhea) and other illness indicators, micronutrient levels, diet, socioeconomic status, gut function, and the environment. MAL-ED aims to describe these factors, their interrelationships, and their overall impact on health outcomes in unprecedented detail, and to make individual, site-specific, and generalized recommendations regarding the nature and timing of possible interventions aimed at improving child health and development in these resource-poor settings.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Status of vaccine research and development for Shigella.

              Shigella are gram-negative bacteria that cause severe diarrhea and dysentery. In 2013, Shigella infections caused an estimated 34,400 deaths in children less than five years old and, in 2010, an estimated 40,000 deaths in persons older than five years globally. New disease burden estimates from newly deployed molecular diagnostic assays with increased sensitivity suggest that Shigella-associated morbidity may be much greater than previous disease estimates from culture-based methods. Primary prevention of this disease should be based on universal provision of potable water and sanitation methods and improved personal and food hygiene. However, an efficacious and low-cost vaccine would complement and accelerate disease reduction while waiting for universal access to water, sanitation, and hygiene improvements. This review article provides a landscape of Shigella vaccine development efforts. No vaccine is yet available, but human and animal challenge-rechallenge trials with virulent Shigella as well as observational studies in Shigella-endemic areas have shown that the incidence of disease decreases following Shigella infection, pointing to biological feasibility of a vaccine. Immunity to Shigella appears to be strain-specific, so a vaccine that covers the most commonly detected strains (i.e., S. flexneri 2a, 3a, 6, and S. sonnei) or a vaccine using cross-species conserved antigens would likely be most effective. Vaccine development and testing may be accelerated by use of animal models, such as the guinea pig keratoconjunctivitis or murine pneumonia models. Because there is no correlate of protection, however, human studies will be necessary to evaluate vaccine efficacy prior to deployment. A diversity of Shigella vaccine constructs are under development, including live attenuated, formalin-killed whole-cell, glycoconjugate, subunit, and novel antigen vaccines (e.g., Type III secretion system and outer membrane proteins).
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet Glob Health
                Lancet Glob Health
                The Lancet. Global Health
                Elsevier Ltd
                2214-109X
                01 October 2018
                December 2018
                01 October 2018
                : 6
                : 12
                : e1319-e1328
                Affiliations
                [a ]Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA
                [b ]Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA
                [c ]Aga Khan University, Karachi, Pakistan
                [d ]Armed Forces Research Institute of Medical Sciences (AFRIMS), Bangkok, Thailand
                [e ]Asociación Benéfica PRISMA, Iquitos, Peru
                [f ]International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh
                [g ]Christian Medical College, Vellore, India
                [h ]University of Venda, Thohoyandou, South Africa
                [i ]Haydom Global Health Institute, Haydom, Tanzania
                [j ]Kilimanjaro Clinical Research Institute, Moshi, Tanzania
                [k ]Federal University of Ceara, Fortaleza, Brazil
                [l ]Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, Brazil
                [m ]Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
                [n ]Fogarty International Center, National Institutes of Health, Bethesda, MD, USA
                [o ]Foundation for the National Institutes of Health, Bethesda, MD, USA
                [p ]National Institute for Communicable Diseases, Johannesburg, South Africa
                [q ]Walter Reed/AFRIMS Research Unit, Nepal, Kathmandu, Nepal
                [r ]University of Bergen, Bergen, Norway
                Author notes
                [* ]Correspondence to: Prof Eric R Houpt, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA 22908, USA erh6k@ 123456hscmail.mcc.virginia.edu
                [*]

                Contributed equally

                [†]

                Members listed in the appendix

                Article
                S2214-109X(18)30351-6
                10.1016/S2214-109X(18)30351-6
                6227248
                30287125
                da3f4243-d2b6-4878-b7dc-e1d5224666d7
                © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                Categories
                Article

                Comments

                Comment on this article

                scite_

                Similar content232

                Cited by174

                Most referenced authors625